Histamine is an inhibitor of NADPH oxidase (NOX2) and has been approved in Europe in conjunction with interleukin-2 for relapse prevention in patients with acute myeloid leukemia (Stadtmauer, 2002). Here, FMO5 is linked to acute myeloid leukemia.